---
document_datetime: 2023-09-21 19:21:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/spinraza-epar-all-authorised-presentations_en.pdf
document_name: spinraza-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6883148
conversion_datetime: 2025-12-22 16:39:08.971053
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Number   | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/17/1188/001 | Spinraza          | 12 mg      | Solution for injection | Intrathecal use           | Vial (glass)          | 5 ml (2.4 mg/ml)          | 1 vial      |